NCT06671938 - Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

March 16, 2026

Study Completion Date

March 16, 2026

Conditions

Parkinson DiseaseMultiple System Atrophy

Interventions

DRUG

exidavnemab

The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)

DRUG

Placebo Comparator

The trial medication will be administered as an intravenous (IV) infusion

Trial Locations (8)

RECRUITING

Policlínica Gipuzkoa, San Sebastián

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

RECRUITING

Hospital Universitario Virgen del Rocío, Seville

RECRUITING

Centrum Medyczyne Neuromed Sp. z o.o., Bydgoszcz

WITHDRAWN

Specjalistyczne Gabinety Sp. z o.o., Krakow

RECRUITING

Krakowska Akademia Neurologii Sp. Z o.o, Krakow

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

RECRUITING

Hospital Universitari General de Catalunya, Sant Cugat del Vallès